ASL Pharma Launches New Brand and KL HQ to Anchor Regional Expansion

KUALA LUMPUR, 16,  March 2026 – ASL Pharma Sdn Bhd today officially unveiled its new brand identity alongside the opening of its new headquarters at Menara 1 Dutamas, Kuala Lumpur, marking a defining milestone in the company’s continued evolution as a standards-driven compounding pharmacy.

Building on more than a decade of experience in personalised medicine, the refreshed brandreflects ASL Pharma’s progression into a more structured, clinically governed and quality-focused organisation. The new Kuala Lumpur headquarters strengthens the company’soperational foundation and supports its next phase of disciplined, regionally focused growth.

Stephanie Yang, Group Chief Executive Officer of ASL Pharma, said, “The opening of our new Kuala Lumpur office marks an important milestone for ASL Pharma and reflects how we have evolved over the years into a more focused, standards-driven healthcareorganisation. This journey has always been guided by a belief that personalised medicine should be delivered with care, discipline and responsibility.”

ASL Pharma – Work of team

“The meaning behind ASL reflects clarity, focus and simplicity., From our base in Malaysia, we are taking a measured and responsible approach to regional expansion, with the Philippines and Indonesia as our initial focus markets. As we grow, we remain guided by the trust of our healthcare partners and the dedication of our team,” she said. 

Andrew Lim, Chief Executive Officer and Co-Founder of ASL Pharma, said, “This milestone reflects the years of work our team has put into building a strong and disciplined operational foundation. Bringing our teams together in this new headquarters strengthens how we collaborate and support our healthcare partners as we prepare for the next phase of growth. Our focus is on building trusted partnerships, maintaining disciplined execution and ensuring that as we expand, we continue to uphold the standards that define our work.”

Gus Bassani, PharmD, Chief Executive Officer of Professional Compounding Centers of America (PCCA), said, “The continued growth of pharmaceutical compounding in Asia underscores the importance of strong practice standards, education and professional governance. ASL Pharma’s evolution reflects a commitment to structured practice and clinical discipline, which will be increasingly important as personalised medicine continues to develop across the region.”

The new ASL Pharma headquarters spans approximately 6,383 square feet and houses a multidisciplinary team of 23 staff, bringing together operations, clinical support, quality management and regional coordination functions under one roof.

New headquarters

Designed as a purpose-built working environment, the office integrates dedicated spaces for clinical coordination, quality documentation and cross-functional collaboration. Its layout prioritises workflow discipline and process oversight, while enabling close engagement with healthcare professionals and regional partners.

In addition to supporting day-to-day operations, the headquarters also serves as a central engagement hub for practitioners, partners and stakeholders, reinforcing ASL Pharma’s commitment to responsible, well-governed personalised medicine.

ASL Pharma specialises in pharmaceutical compounding, including bioidentical hormone replacement therapy (BHRT) and other customised formulations developed in response to specific patient requirements. Its compounding activities are guided by documented protocols, controlled sourcing of pharmaceutical-grade ingredients and quality assurance processes designed to support consistency, traceability and responsible clinical use.

For more information on ASL Pharma, please visit: https://aslpharma.asia/

Business News